
Retatrutide
Retatrutide is an investigational once-weekly injection that acts on three hormone receptors. In published phase 3 trials lasting up to 80 weeks, adults with obesity lost on average 17.6% to 25.0% of their body weight depending on dose, compared with 3.9% on placebo, and it also reduced knee osteoarthritis pain and sleep apnea events. It is not FDA-approved, and its long-term safety and effects on heart attacks and strokes are not yet known.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with obesity, with or without type 2 diabetes, who qualify for and choose to join a registered clinical trial (or, for a small group with severe obesity, the expanded access program a doctor can request); everyone else can ask a doctor about approved weight-loss medicines
Common dosing range
No approved dose. Phase 3 trials studied 4 mg, 9 mg or 12 mg injected once weekly; outside a trial no dose is established
When to expect effects
Weight loss built over many months; phase 3 results were measured at 40 to 80 weeks
Watch out for
Not FDA-approved and cannot be prescribed as a normal medicine. FDA says it cannot be used in compounding, and products sold online, including "research" vials, are unapproved and of unknown quality. In trials, stomach side effects were common and more people stopped the 9 mg dose than placebo because of side effects
What is it
Retatrutide is an investigational drug that is not FDA-approved for any use, so it cannot be prescribed as a normal medicine, and any product sold now as retatrutide (including vials labeled "for research use only") is unapproved and unverified. FDA says retatrutide cannot be used in compounding under federal law, is not a component of any FDA-approved drug and has not been found safe and effective for any condition; it has warned telehealth companies, ingredient distributors and outsourcing facilities for marketing, selling or repackaging it. Outside clinical trials, the only listed route is a single-patient expanded access program on ClinicalTrials.gov (NCT07629401), limited to adults with a BMI of 35 or more and at least two serious obesity-related complications that have not responded to the best approved treatment, who cannot join a trial. Its developer, Eli Lilly, is testing it in phase 3 trials as a once-weekly injection for obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea and other conditions. Several phase 3 trials have been published in 2026, and others, including a trial of heart and kidney outcomes and a head-to-head trial against tirzepatide, are still running on ClinicalTrials.gov.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
weight loss in adults with obesity without diabetes Good Evidence | 21.0 percentage points more weight loss than placebo with 12 mg and 19.8 points with 9 mg at 80 weeks (TRIUMPH-1) | Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes | Measured at 48 to 80 weeks; weight was still falling at 48 weeks in phase 2 |
weight and blood sugar in type 2 diabetes Good Evidence | HbA1c 0.88 to 1.12 percentage points lower than placebo at 40 weeks; body weight 6.9 to 13.8 percentage points lower than placebo at 80 weeks | Adults with type 2 diabetes and overweight or obesity on diet and exercise or oral diabetes medicines | HbA1c measured at 24 to 40 weeks; weight at 36 to 80 weeks |
knee osteoarthritis pain with obesity Good Evidence | WOMAC pain 1.61 to 1.83 points lower than placebo at 68 weeks (hybrid estimand); 1.38 to 1.70 points (intention to treat) | Adults with painful knee osteoarthritis and a BMI of 27 or more | Measured at 68 to 80 weeks |
obstructive sleep apnea with obesity Good Evidence | 21.9 to 24.4 fewer events an hour than placebo without diabetes; 14.4 to 15.1 fewer with type 2 diabetes (9 mg and 12 mg) | Adults with moderate to severe sleep apnea and a BMI of 27 or more | Measured at 80 weeks |
weight loss in adults with obesity without diabetes
- Effect
- 21.0 percentage points more weight loss than placebo with 12 mg and 19.8 points with 9 mg at 80 weeks (TRIUMPH-1)
- Best fit
- Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
- Time
- Measured at 48 to 80 weeks; weight was still falling at 48 weeks in phase 2
weight and blood sugar in type 2 diabetes
- Effect
- HbA1c 0.88 to 1.12 percentage points lower than placebo at 40 weeks; body weight 6.9 to 13.8 percentage points lower than placebo at 80 weeks
- Best fit
- Adults with type 2 diabetes and overweight or obesity on diet and exercise or oral diabetes medicines
- Time
- HbA1c measured at 24 to 40 weeks; weight at 36 to 80 weeks
knee osteoarthritis pain with obesity
- Effect
- WOMAC pain 1.61 to 1.83 points lower than placebo at 68 weeks (hybrid estimand); 1.38 to 1.70 points (intention to treat)
- Best fit
- Adults with painful knee osteoarthritis and a BMI of 27 or more
- Time
- Measured at 68 to 80 weeks
obstructive sleep apnea with obesity
- Effect
- 21.9 to 24.4 fewer events an hour than placebo without diabetes; 14.4 to 15.1 fewer with type 2 diabetes (9 mg and 12 mg)
- Best fit
- Adults with moderate to severe sleep apnea and a BMI of 27 or more
- Time
- Measured at 80 weeks
Evidence for 4 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
weight loss in adults with obesity without diabetes
Disease adjunctIn TRIUMPH-1, a phase 3 trial of 2339 adults with obesity and without diabetes, once-weekly retatrutide for 80 weeks lowered body weight by an average of 17.6% (4 mg), 23.7% (9 mg) and 25.0% (12 mg), compared with 3.9% on placebo. In TRIUMPH-4, 445 adults with obesity or overweight (BMI of 27 or more) and knee osteoarthritis lost 20.0% (9 mg) and 23.7% (12 mg) at 68 weeks, compared with 4.6% on placebo. In the earlier 48-week phase 2 trial of 338 adults, 83% of those on 12 mg lost at least 15% of their weight, compared with 2% on placebo. All three trials were funded by Eli Lilly. They did not test heart attacks, strokes or deaths, and no results after stopping the drug are published.
Bottom line: Large average weight loss in phase 3 trials, but only up to 80 weeks and without heart outcome data.
weight and blood sugar in type 2 diabetes
Biomarker supportIn TRIUMPH-2, 1152 adults with obesity or overweight and type 2 diabetes (average HbA1c 7.71%) lost 11.9% (4 mg), 16.8% (9 mg) and 18.8% (12 mg) of their body weight over 80 weeks, compared with 5.1% on placebo. In TRANSCEND-T2D-1, 537 adults with type 2 diabetes not controlled by diet and exercise lowered HbA1c by 1.69 to 1.94 percentage points over 40 weeks, compared with 0.81 on placebo, and lost 11.5% to 15.3% of body weight, compared with 2.6%. In a 36-week phase 2 trial of 281 people in the USA, the 8 mg (slow step-up) and 12 mg doses lowered HbA1c more than dulaglutide 1.5 mg at 24 weeks. The trials were funded by Eli Lilly and did not measure diabetes complications.
Bottom line: It lowered blood sugar and weight in type 2 diabetes; effects on eye, kidney and heart complications are not yet known.
knee osteoarthritis pain with obesity
Disease adjunctIn two phase 3 trials (TRIUMPH-4 with 445 adults and TRIUMPH-1-OA with 574 adults, all with painful knee osteoarthritis and obesity or overweight, without diabetes), retatrutide reduced the WOMAC knee pain score (0 to 10 scale) more than placebo. At 68 weeks in TRIUMPH-4 the pain score fell by 3.96 (9 mg) and 3.74 (12 mg), compared with 2.12 on placebo. Pain fell substantially on placebo too, so the extra benefit was about 1.4 to 1.8 points. Serious adverse events were more common with retatrutide than with placebo in both trials. The trials did not test joint structure or the need for knee replacement.
Bottom line: Knee pain eased more than with placebo, alongside large weight loss; whether the joint itself changes is unknown.
obstructive sleep apnea with obesity
Disease adjunctIn two phase 3 trials nested inside TRIUMPH-1 (243 adults without diabetes) and TRIUMPH-2 (448 adults with type 2 diabetes), all with moderate to severe sleep apnea (about 56 to 59 breathing events an hour at the start), retatrutide lowered the apnea-hypopnea index more than placebo over 80 weeks. Without diabetes, events fell by 34.3 an hour on 9 mg and 31.7 on 12 mg, compared with 9.9 on placebo; with diabetes, by 24.7 and 25.4, compared with 10.3. The trials were funded by Eli Lilly. On average, people still had more than 20 events an hour at the end, which is still sleep apnea.
Bottom line: Fewer breathing pauses at night than placebo; on average, sleep apnea was still present at the end.
How it works
How to take it
What to track
Bottom line: Large weight losses in trials, but it is an unapproved drug: a registered clinical trial (or, for a small group with severe obesity, a doctor-requested expanded access program) is the only legitimate route now.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Stopping because of side effects. In TRIUMPH-2, 12% on 9 mg and 8% on 12 mg stopped permanently because of adverse events or death, compared with 4% on 4 mg and 5% on placebo. In the knee osteoarthritis trials, serious adverse events were more common with retatrutide than with placebo.
Unknown long-term and heart safety. The longest published trials lasted 80 weeks. A trial of heart and kidney outcomes in about 10,000 adults is still running, with its primary completion estimated on ClinicalTrials.gov as February 2029, and no results after stopping the drug are published.
Class warning, not a finding for retatrutide: approved drugs acting on the GLP-1 receptor, such as tirzepatide, carry a boxed warning because they caused thyroid C-cell tumors in rodents, and they are not used in people with a personal or family history of medullary thyroid cancer or MEN 2. Retatrutide trials excluded these people.
Class warnings, not findings for retatrutide: the labels of approved GLP-1 medicines warn of pancreatitis, gallbladder disease, dehydration leading to kidney injury, low blood sugar when combined with insulin or a sulfonylurea, severe stomach side effects (not recommended with severe gastroparesis), serious allergic reactions, worsening of diabetic eye disease (retinopathy) in people with type 2 diabetes, and food entering the lungs during anesthesia or deep sedation. People who had had pancreatitis were excluded from TRIUMPH-1.
Unapproved products of unknown quality. FDA says retatrutide cannot be used in compounding and has warned companies that illegally sold unapproved drugs containing retatrutide falsely labeled "for research purposes" or "not for human consumption" for human use; FDA says these products are of unknown quality and may be harmful. FDA also warns that illegally marketed GLP-1 drugs sold online may be counterfeit or contain the wrong ingredients or the wrong amount.
Who should avoid it
- Anyone outside a registered clinical trial or the expanded access program, because the drug is not approved and products sold elsewhere are unapproved
- People with a personal or family history of medullary thyroid cancer or MEN 2 (excluded from the trials; a contraindication for approved drugs in the class)
- People who have had pancreatitis (excluded from TRIUMPH-1)
- People who are pregnant, planning a pregnancy or breastfeeding: no human data are published, and labels of approved drugs in the class say they may cause fetal harm
Pregnancy & breastfeeding
Pregnancy: no data on retatrutide in pregnancy are published. As a class warning, the labels of approved weight-loss drugs in this family say they may cause fetal harm; the Zepbound (tirzepatide) label says to stop when pregnancy is recognized. Breastfeeding: no data on retatrutide in breast milk or in breastfed infants are published.
Interactions
Class-based, not a finding for retatrutide: the Wegovy (semaglutide) and Zepbound (tirzepatide) labels say that use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of low blood sugar, including severe low blood sugar, and that reducing the dose of the insulin or secretagogue may be necessary. Retatrutide has no FDA label. In the published trial of retatrutide alone in type 2 diabetes (TRANSCEND-T2D-1), no severe low blood sugar was reported.
Class-based, not a finding for retatrutide: retatrutide acts on the GLP-1 receptor. The Wegovy label says use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. TRIUMPH-1 excluded people who had taken weight-loss drugs in the 90 days before screening.
Class-based, not a finding for retatrutide: the Zepbound label says tirzepatide delays stomach emptying and may affect the absorption of medicines taken by mouth, and says to monitor people taking oral medicines with a narrow therapeutic index (for example warfarin); the Wegovy label says to consider increased clinical or laboratory monitoring with such medicines. A study of retatrutide with warfarin, midazolam and caffeine is listed as completed on ClinicalTrials.gov (NCT05445232), but no results are posted or published. The Zepbound label also advises people using birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. A study of retatrutide with a combined birth control pill is listed as completed on ClinicalTrials.gov (NCT06039826), but no results are posted or published.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is retatrutide FDA-approved?⌄
No. As of November 19, 2026, it does not appear among FDA's approved drugs, and FDA states that it is not a component of any FDA-approved drug and has not been found safe and effective for any condition. It is in phase 3 trials run by Eli Lilly. Only FDA can decide whether it is approved.
Is it legal to buy retatrutide online?⌄
Retatrutide is an unapproved drug. FDA says it cannot be used in compounding under federal law, and it has warned telehealth companies, ingredient distributors and sellers of "research" products for marketing it. FDA urges people not to buy these products, which are of unknown quality. A registered clinical trial is the main legitimate way to receive it now; Lilly also lists a single-patient expanded access program (NCT07629401) that a doctor can request only for adults with severe obesity who meet strict criteria and cannot join a trial.
How does retatrutide compare with tirzepatide or semaglutide?⌄
It acts on the same GLP-1 and GIP receptors as tirzepatide plus the glucagon receptor. In its phase 3 obesity trial, average weight loss at 80 weeks was 23.7% on 9 mg and 25.0% on 12 mg. Numbers from different trials cannot be compared directly, though: a head-to-head trial against tirzepatide (TRIUMPH-5) is listed on ClinicalTrials.gov and its results are not published yet.
Can I join a retatrutide trial?⌄
Trials are listed on ClinicalTrials.gov, including some still recruiting. Each trial has its own entry rules: for example, TRIUMPH-1 excluded people with diabetes, a history of pancreatitis, or a personal or family history of medullary thyroid cancer or MEN 2. Your doctor can help you judge whether a trial fits you.
Can I take retatrutide with my supplements or other medicines?⌄
No interaction studies of retatrutide with supplements have been published. Based on the labels of approved drugs in the same family, low blood sugar is a risk with insulin or sulfonylureas, the labels say using it with another GLP-1 medicine is not recommended, and slower stomach emptying may affect medicines taken by mouth. Ask a doctor or pharmacist to check your own list.
Does the weight stay off after stopping?⌄
That is not known yet. No published retatrutide trial has reported what happens after the drug is stopped. In SURMOUNT-4, a withdrawal trial of the approved drug tirzepatide published in JAMA in 2024, adults who switched to placebo after 36 weeks of treatment regained an average of 14.0% of their body weight over the next 52 weeks, while those who stayed on tirzepatide lost a further 5.5%. A retatrutide trial of weight maintenance (TRIUMPH-6) is listed on ClinicalTrials.gov.
References by claim
weight loss in adults with obesity without diabetes
weight and blood sugar in type 2 diabetes
obstructive sleep apnea with obesity
Grunstein et al., 2026 · PubMed (2026) link
Safety
ClinicalTrials.gov record NCT06383390: effect of retatrutide on cardiovascular and kidney outcomes · ClinicalTrials.gov link
Zepbound (tirzepatide) prescribing information · DailyMed (FDA label) link
ClinicalTrials.gov record NCT05929066 (TRIUMPH-1): eligibility criteria · ClinicalTrials.gov link
Wegovy (semaglutide) injection and tablets prescribing information · DailyMed (FDA label) link
FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss · FDA link
ClinicalTrials.gov record NCT07629401: pre-approval single-patient expanded access of retatrutide · ClinicalTrials.gov link
Interaction: Oral medicines with a narrow safety margin (such as warfarin) and birth control pills
Track Retatrutide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
